Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We show that intensification of treatment with maraviroc in patients chronically infected with HIV-1 receiving successful long-term antiretroviral therapy was not associated with improvements in HIV-related morbidity, HIV reservoir, microbial translocation, immune activation, or immune exhaustion in either gut or peripheral blood. The measurement of reservoir in both gut and blood longitudinally contributes to a paucity of data in the area.

Original publication




Journal article


AIDS Res Hum Retroviruses

Publication Date





143 - 146


HIV, antiretroviral therapy, immune activation, microbial translocation, viral reservoirs, Blood, CCR5 Receptor Antagonists, Cyclohexanes, Gastrointestinal Tract, HIV Infections, Humans, Male, Maraviroc, Middle Aged, Pilot Projects, Prospective Studies, Treatment Outcome, Triazoles